Tuesday, July 17, 2018
 
 
Company News: Page (1) of 1 - 07/12/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Fibromyalgia Therapeutics - Global Strategic Business Report 2018-2022 - ResearchAndMarkets.com

(July 12, 2018)

DUBLIN--(BUSINESS WIRE)--The "Fibromyalgia Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.


Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for this market. The report analyzes the Global market for Fibromyalgia Therapeutics in US$ Million.

The report profiles 22 companies including many key and niche players such as:

  • Allergan plc (Ireland)
  • Boehringer Ingelheim GmbH (Germany)
  • Daiichi Sankyo Company Limited (Japan)
  • Eli Lilly and Company (USA)
  • Innovative Med Concepts, Inc. (USA)
  • Pfizer, Inc. (USA)
  • Pierre Fabre Mdicament (France)
  • SWITCHBIOTECH LLC (USA)
  • Zynerba Pharmaceuticals, Inc. (USA)

Key Topics Covered



1. INDUSTRY OVERVIEW

Fibromyalgia Syndrome: A Prelude

Fibromyalgia Therapeutics Market: A Nascent Sector

A Glance at the Current & Future Fibromyalgia Therapeutics Portfolio

FDA Approved Fibromyalgia Drugs

IMC-1: A Revolutionary Combination Therapy

Daiichi Sankyo's Mirogabalin Drug Improvises on Lyrica

Tonix Pharma Develops Newer Sublingual Formulation of Cyclobenzaprine

Understanding Heightened Effect of Pain in Women Due to Fibromyalgia

Inconsistencies and Loopholes in Current Fibromyalgia Diagnoses

Fibromyalgia Treatment through High-Pressure Oxygen Application

EU approves New Device to Treat Fibromyalgia and Migraine

2. AVAILABLE & PIPELINE FIBROMYALGIA DRUGS

AN OVERVIEW

Medications Used in the Fibromyalgia Treatment

Pain Relievers

Antidepressants

Anti-Seizure Drugs

Medication for Improving Sleep

Muscle Relaxants

Antipsychotics

A Glance at Available Fibromyalgia Drugs

Lyrica (pregabalin)

Cymbalta (duloxetine HCl)

Savella (milnacipran HCl)

Fibromyalgia Products in Pipeline

Mirogabalin

IMC-1

SWT06101

3. FIBROMYALGIA

THE DISEASE, SYMPTOMS, AND DIAGNOSIS

4. MANAGEMENT OF FIBROMYALGIA

Non-Pharmacological Treatment of Fibromyalgia

Nutritional Therapy

Exercise

Cognitive Behavior Therapy

Pharmacological Treatment Alternatives for Fibromyalgia

Antidepressants

Tricyclic Antidepressants (TCA)

Dopamine Agonists

Muscle Relaxants

Selective Serotonin-Norephinephrine Inhibitors (SNRIs)

Selective Serotonin Reuptake Inhibitors (SSRIs)

Drug Therapy for Fibromyalgia-Related Fatigue

Other Therapeutic Agents for Fibromyalgia Treatment

Conclusion

5. CLINICAL STUDIES & PRODUCT LAUNCHES/APPROVALS

Cannabis Science Introduces Fibromyalgia Pain Relief Medication

Soterix Medical Launches PainX tDCS Treatment in Canada

Synovation Medical Group to Conduct Study on NeuroMetrix's Quell Wearable Pain Relief Technology

FDA Grants Fast Track Designation to Innovative Med Concepts' IMC-1

Soterix Medical's PainX Treatment Receives CE Mark Approval

Tonix Pharmaceuticals Begins Phase 3 Trial of TNX-102 SL

Pfizer's Lyrica Fails to Meet FDA Requirements in Post- Marketing Study

Premier Biomedical to Submit Application to FDA for Fibromyalgia Therapy

6. FOCUS ON SELECT GLOBAL PLAYERS

Allergan plc (Ireland)

Boehringer Ingelheim GmbH (Germany)

Daiichi Sankyo Company Limited (Japan)

Eli Lilly and Company (USA)

Innovative Med Concepts, Inc. (USA)

Pfizer, Inc. (USA)

Pierre Fabre Mdicament (France)

SWITCHBIOTECH LLC (USA)

Zynerba Pharmaceuticals, Inc. (USA)

7. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 22 (including Divisions/Subsidiaries 23)

  • The United States (12)
  • Canada (1)
  • Japan (4)
  • Europe (5)
    • France (1)
    • Germany (1)
    • Rest of Europe (3)
  • Asia-Pacific (Excluding Japan) (1)

For more information about this report visit https://www.researchandmarkets.com/research/l2ckjn/fibromyalgia?w=4

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.


Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Musculoskeletal Disorders Drugs


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Personal Care Home Consultant Lynn Marting Helps Families Find the Right Facility for Aging Loved Ones
  • HMP's 8th Annual Amputation Prevention Symposium Expected to Draw 800 Clinicians to Chicago to Join the CLI Revolution
  • Progressive Care Inc. Announces Month-End Sales Figures Showing Increase in Year-Over-Year Prescriptions Filled in June 2018
  • Mount Sinai Health System and Arena Address AI-Driven Hiring for Healthcare at Leading Industry Conference
  • Connected Health Devices: Global Market Forecast to 2023 - CAGR to Grow at 21.1%, Driven by the Increasing Adoption of IT in Healthcare

    Cancer
  • Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder
  • Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer
  • Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer
  • Corporate Whistleblower Center Now Targets Hospice Providers Ripping Off Medicare And Urges Their Employees with Proof a of Wrongdoing to Call About Rewards -- Don't Get Mad, Get Even
  • Corporate Whistleblower Center Now Targets Hospice Providers Ripping Off Medicare And Urges Their Employees with Proof a of Wrongdoing to Call About Rewards -- Don't Get Mad, Get Even
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines